Last checked at 11 Apr 2012 15:50
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation for the second trading quarter to 31st March 2012
Tom Winnifrith, Chief Investment Officer, commented: -
"The Net Asset Value calculation for the Company as at closing on 31st March 2012 is 9.59 pence per share, an increase of 12.0% since the last valuation.
This is again a satisfactory result, reflecting both a cumulative profit since inception of £162,086 and also a growth in Net Assets of £338,007 since the last quarter's valuation. We have now invested the bulk of the cash, leaving £486,580 remaining for further opportunities.
The market performance of both Arrowhead Research, a nanomedicine company with developments in RNAi therapeutics and obesity control; and Plethora Solutions, specialising in products for the treatment and management of urological disorders, where Jim Mellon has joined the board, is particularly noteworthy. Both companies have recently reported positive progress which is very encouraging."
| Unaudited 15 September to 31 March 2012 £ | |
Fixed Assets |
|
|
| Investments
| 2,673,633 |
Current Assets |
|
|
| Sundry Debtors | 12,123 |
| Uninvested cash
| 486,580 |
Current Liabilities |
|
|
| Creditors: amounts due
| (9,250) |
|
| 3,163,086 |
Capital and Reserves |
|
|
| Share Capital | 33 |
| Share Premium | 3,000,967 |
| Capital reserve - realised | 0 |
| Capital reserve - unrealised | 0 |
| Revenue reserve
| 162,086 |
| 3,163,086
| |
| ||
Shares in Issue
| 33,000,000 | |
Net Asset Value per share | 9.59 pence |
Company | ValuationGBP | % ofPortfolio |
Arrowhead Research | £396,299.56 | 14.8% |
Pfizer Inc. | £207,329.58 | 7.8% |
Plethora Solutions | £190,356.47 | 7.1% |
Novartis AG | £156,362.73 | 5.9% |
Synergy Pharmaceuticals Inc. | £140,485.93 | 5.3% |
Astellas Pharma Inc. | £133,810.51 | 5.0% |
Abbott Laboratories | £110,794.87 | 4.1% |
Merck & Co. Inc. | £91,043.15 | 3.4% |
Onyx Pharmaceuticals | £86,093.81 | 3.2% |
Nektar Therapeutics | £85,628.52 | 3.2% |
H Lundebeck A/S | £72,500.31 | 2.7% |
Immunocellular Therapeutics Ltd. | £68,445.90 | 2.6% |
Celgene Corp. | £68,231.39 | 2.6% |
Map Pharmaceuticals Inc. | £67,796.12 | 2.5% |
Eli Lilly & Co. | £66,788.62 | 2.5% |
Medivir AB-B | £65,701.06 | 2.5% |
Shire plc | £64,320.20 | 2.4% |
Rigel Pharmaceutical Inc. | £63,784.87 | 2.4% |
Ampliphi Biosciences Corp. | £62,539.09 | 2.3% |
Synergy Pharmaceuticals Inc. | £58,712.32 | 2.2% |
Polymedix Inc. | £53,683.55 | 2.0% |
Pharmathene Inc. | £51,829.27 | 1.9% |
Medivation Inc. | £50,700.44 | 1.9% |
Siga Technologies Inc. | £49,193.25 | 1.8% |
Miraculins Inc. | £34,224.52 | 1.3% |
Synta Pharmaceuticals Corp. | £31,774.86 | 1.2% |
Spiritus Pharmaceuticals, LLC | £31,269.54 | 1.2% |
Pacific Biosciences California Inc. | £28,026.89 | 1.1% |
Biotime Inc. | £27,747.34 | 1.0% |
Methylgene Inc. | £24,470.92 | 0.9% |
Complete Genomics Inc. | £23,386.49 | 0.9% |
Synergy warrants (publicly traded) | £10,300.81 | 0.4% |
TOTAL INVESTMENTS | £2,673,632.89 |
ENDS
For further information, please contact:
Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Rivington Street Corporate Finance Limited |
The Company | Nomad | Broker |
Tom Winnifrith +44 7624 355306 | Sandy Jamieson +44 207 569 9650 | Jon Levinson +44 207 562 3350 |